BLCO News and Press, Bausch + Lomb Corporation

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the pre...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material inf...

2024-06-09 10:44:45 ET Summary Carl Icahn's 13F filing shows 14 holdings, including Icahn Enterprises, CVR Energy, Southwest Gas Holdings, Occidental Petroleum warrants, and Bausch Health. Icahn established a new stake in JetBlue Airways this quarter. Also, a significant position ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes health...

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholde...

2024-05-29 10:45:04 ET Childrens Place Inc (PLCE) PLCE is trading UP for the last 5 days, and it at trading at $9.37 with volume of 1,269,597 and a one day change of $1.37 (17.13%). Childrens Place Inc has a 52-week low of 6.59 and a 52-week high of $38.03. The business's 50-day mov...

15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears ® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO ® (Perfluorohexyloctane Ophthalmic Solution) Bausch + Lomb Corporation (NYSE/TSX: BLCO), ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista ® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory...

2024-05-24 12:12:17 ET Summary Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. Th...

2024-05-22 16:31:48 ET Summary Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuti...